Login to Your Account

Aiming at Soliris, Apellis loads for PNH phase III with $60M

By Marie Powers
News Editor

Thursday, August 10, 2017

Apellis Pharmaceuticals Inc. extended its string of financings with a $60 million series E preferred stock round led by Sectoral Asset Management that included new investors Sofinnova, Vivo Capital, F-Prime Capital Partners, investment funds advised by Clough Capital Partners LP and Venbio Select.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription